The Latin America, Middle East and Africa Vascular Patches Market should witness market growth of 9.1% CAGR during the forecast period (2022-2028).
The qualities of new-generation patches drive late degeneration, and they have long-term stability, durability, easy handling properties, minimal risk of ischemic strokes, and better usage. The demand for these vascular devices has increased as a result of how well they have helped surgeons perform cardiovascular surgeries.
The aforementioned considerations thus have an impact on the market for vascular patches and, therefore, would continue to do so during the upcoming years. The development of novel products and technologies that are suitable for use and for strategic partnerships through technology transfer activities are considerations that favor vascular patch manufacturers to grow their businesses.
This propels the increase in sales growth in addition to the market positioning for leading manufacturers within the vascular patch industry. The development of vascular surgery techniques and the treatment of vascular diseases will be influenced by impending technological developments. Superior medical interventions to halt or even combat atherosclerosis are on the horizon.
According to estimates, non-communicable diseases (NCDs), including CVDs, cause 74% of all adult fatalities in Brazil. Thirty-eight percent (30.8%) of the population suffers from hypertension, which raises the risk of heart failure, heart attack, kidney illness, and stroke. In Brazil, 18.8% of adults are obese, with adult women being more likely to be obese (21.4%) than males (16%). More people are developing type 2 diabetes in Brazil as a result of the country's rising obesity rates; it is estimated approximately 8.8% of females and 7.4% of males have the disease.
The Brazil market dominated the LAMEA Vascular Patches Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $7, 755.1 Thousands by 2028. The Argentina market is experiencing a CAGR of 9.7% during (2022-2028). Additionally, The UAE market would display a CAGR of 8.8% during (2022-2028).
Based on Material, the market is segmented into Biologic and Synthetic. Based on End-user, the market is segmented into Hospitals and Ambulatory Surgical Centers. Based on Application, the market is segmented into Carotid Endarterectomy, Open Repair of Abdominal Aortic Aneurysm, Vascular Bypass Surgery, Congenital Heart Disease and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Edwards Lifesciences Corporation, Baxter International, Inc., Lemaitre Vascular, Inc., Becton, Dickinson and Company, Terumo Corporation, Aziyo Biologics, Inc., Getinge AB, B. Braun Melsungen AG, Artivion, Inc. (CryoLife, Inc.), and W. L. Gore & Associates, Inc.
The qualities of new-generation patches drive late degeneration, and they have long-term stability, durability, easy handling properties, minimal risk of ischemic strokes, and better usage. The demand for these vascular devices has increased as a result of how well they have helped surgeons perform cardiovascular surgeries.
The aforementioned considerations thus have an impact on the market for vascular patches and, therefore, would continue to do so during the upcoming years. The development of novel products and technologies that are suitable for use and for strategic partnerships through technology transfer activities are considerations that favor vascular patch manufacturers to grow their businesses.
This propels the increase in sales growth in addition to the market positioning for leading manufacturers within the vascular patch industry. The development of vascular surgery techniques and the treatment of vascular diseases will be influenced by impending technological developments. Superior medical interventions to halt or even combat atherosclerosis are on the horizon.
According to estimates, non-communicable diseases (NCDs), including CVDs, cause 74% of all adult fatalities in Brazil. Thirty-eight percent (30.8%) of the population suffers from hypertension, which raises the risk of heart failure, heart attack, kidney illness, and stroke. In Brazil, 18.8% of adults are obese, with adult women being more likely to be obese (21.4%) than males (16%). More people are developing type 2 diabetes in Brazil as a result of the country's rising obesity rates; it is estimated approximately 8.8% of females and 7.4% of males have the disease.
The Brazil market dominated the LAMEA Vascular Patches Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $7, 755.1 Thousands by 2028. The Argentina market is experiencing a CAGR of 9.7% during (2022-2028). Additionally, The UAE market would display a CAGR of 8.8% during (2022-2028).
Based on Material, the market is segmented into Biologic and Synthetic. Based on End-user, the market is segmented into Hospitals and Ambulatory Surgical Centers. Based on Application, the market is segmented into Carotid Endarterectomy, Open Repair of Abdominal Aortic Aneurysm, Vascular Bypass Surgery, Congenital Heart Disease and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Edwards Lifesciences Corporation, Baxter International, Inc., Lemaitre Vascular, Inc., Becton, Dickinson and Company, Terumo Corporation, Aziyo Biologics, Inc., Getinge AB, B. Braun Melsungen AG, Artivion, Inc. (CryoLife, Inc.), and W. L. Gore & Associates, Inc.
Scope of the Study
By Material
- Biologic
- Synthetic
By End-user
- Hospitals
- Ambulatory Surgical Centers
By Application
- Carotid Endarterectomy
- Open Repair of Abdominal Aortic Aneurysm
- Vascular Bypass Surgery
- Congenital Heart Disease
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Edwards Lifesciences Corporation
- Baxter International, Inc.
- Lemaitre Vascular, Inc.
- Becton, Dickinson and Company
- Terumo Corporation
- Aziyo Biologics, Inc.
- Getinge AB
- B.Braun Melsungen AG
- Artivion, Inc. (CryoLife, Inc.)
- W.L. Gore & Associates, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Vascular Patches Market, by Material
1.4.2 LAMEA Vascular Patches Market, by End User
1.4.3 LAMEA Vascular Patches Market, by Application
1.4.4 LAMEA Vascular Patches Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Vascular Patches Market
Chapter 4. LAMEA Vascular Patches Market by Material
4.1 LAMEA Biologic Market by Country
4.2 LAMEA Synthetic Market by Country
Chapter 5. LAMEA Vascular Patches Market by End User
5.1 LAMEA Hospitals Market by Country
5.2 LAMEA Ambulatory Surgical Centers Market by Country
Chapter 6. LAMEA Vascular Patches Market by Application
6.1 LAMEA Carotid Endarterectomy Market by Country
6.2 LAMEA Open Repair of Abdominal Aortic Aneurysm Market by Country
6.3 LAMEA Vascular Bypass Surgery Market by Country
6.4 LAMEA Congenital Heart Disease Market by Country
6.5 LAMEA Others Market by Country
Chapter 7. LAMEA Vascular Patches Market by Country
7.1 Brazil Vascular Patches Market
7.1.1 Brazil Vascular Patches Market by Material
7.1.2 Brazil Vascular Patches Market by End User
7.1.3 Brazil Vascular Patches Market by Application
7.2 Argentina Vascular Patches Market
7.2.1 Argentina Vascular Patches Market by Material
7.2.2 Argentina Vascular Patches Market by End User
7.2.3 Argentina Vascular Patches Market by Application
7.3 UAE Vascular Patches Market
7.3.1 UAE Vascular Patches Market by Material
7.3.2 UAE Vascular Patches Market by End User
7.3.3 UAE Vascular Patches Market by Application
7.4 Saudi Arabia Vascular Patches Market
7.4.1 Saudi Arabia Vascular Patches Market by Material
7.4.2 Saudi Arabia Vascular Patches Market by End User
7.4.3 Saudi Arabia Vascular Patches Market by Application
7.5 South Africa Vascular Patches Market
7.5.1 South Africa Vascular Patches Market by Material
7.5.2 South Africa Vascular Patches Market by End User
7.5.3 South Africa Vascular Patches Market by Application
7.6 Nigeria Vascular Patches Market
7.6.1 Nigeria Vascular Patches Market by Material
7.6.2 Nigeria Vascular Patches Market by End User
7.6.3 Nigeria Vascular Patches Market by Application
7.7 Rest of LAMEA Vascular Patches Market
7.7.1 Rest of LAMEA Vascular Patches Market by Material
7.7.2 Rest of LAMEA Vascular Patches Market by End User
7.7.3 Rest of LAMEA Vascular Patches Market by Application
Chapter 8. Company Profiles
8.1 Edwards Lifesciences Corporation
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Product Launches and Product Expansions:
8.1.5.2 Acquisition and Mergers:
8.2 Baxter International, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Acquisition and Mergers:
8.3 Lemaitre Vascular, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Acquisition and Mergers:
8.4 Becton, Dickinson and Company
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Acquisition and Mergers:
8.5 Terumo Corporation
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Regional Analysis
8.5.5 Recent strategies and developments:
8.5.5.1 Product Launches and Product Expansions:
8.6 Aziyo Biologics, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Research & Development Expenses
8.7 Getinge AB
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.8 B. Braun Melsungen AG
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expenses
8.9 Artivion, Inc. (CryoLife, Inc.)
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expenses
8.10. W. L. Gore & Associates, Inc.
8.10.1 Company Overview
8.10.2 Recent strategies and developments:
8.10.2.1 Acquisition and Mergers:
Companies Mentioned
- Edwards Lifesciences Corporation
- Baxter International, Inc.
- Lemaitre Vascular, Inc.
- Becton, Dickinson and Company
- Terumo Corporation
- Aziyo Biologics, Inc.
- Getinge AB
- B. Braun Melsungen AG
- Artivion, Inc. (CryoLife, Inc.)
- W. L. Gore & Associates, Inc.
